Michael Jeng

Publication Details

  • Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis. Pediatric blood & cancer Abraham, A., Alsultan, A., Jeng, M., Rodriguez-Galindo, C., Campbell, P. K. 2013; 60 (6): E19-22


    Pediatric patients with refractory multisystem Langerhans cell histiocytosis (LCH) have a poor prognosis despite aggressive chemotherapy. Salvage therapy with cytarabine and cladribine has shown promise as an effective treatment but is associated with significant toxicity. A previous report described two patients with refractory LCH who had a rapid response to single-agent clofarabine with minimal toxicity. In this report, we describe four children with refractory, risk-organ-positive LCH who were treated with clofarabine and provide follow-up for the two previously reported cases. The results support development of a formal trial evaluating clofarabine as front-line salvage for refractory LCH.

    View details for DOI 10.1002/pbc.24436

    View details for PubMedID 23255383

Stanford Medicine Resources:

Footer Links: